Anaplastic Lymphoma Kinase Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Anaplastic Lymphoma Kinase clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.40 enrolled8 locationsNCT07140016
Recruiting
Phase 3

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc.450 enrolled112 locationsNCT06765109
Recruiting

A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Carcinoma, Non-Small Cell LungAnaplastic Lymphoma Kinase
Takeda257 enrolled1 locationNCT04592523
Recruiting
Phase 1Phase 2

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Colorectal, CancerHepatocellular CarcinomaMelanoma+15 more
7 Hills Pharma, LLC126 enrolled4 locationsNCT06362369
Recruiting
Phase 1

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Anaplastic Large Cell LymphomaAnaplastic Lymphoma Kinase
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT07001384
Recruiting
Phase 4

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

Lung CancerCarcinoma, Non-Small Cell LungDrug Monitoring+2 more
University Medical Center Groningen196 enrolled8 locationsNCT05525338
Recruiting

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Carcinoma, Non-Small Cell LungAnaplastic Lymphoma Kinase I1171NEnsartinib
Peking Union Medical College Hospital490 enrolled1 locationNCT05498064